Human leukocyte antigen class II-human cytomegalovirus peptide complex (HLA-II-HCMV complex)

Human leukocyte antigen (HLA) class II molecules presenting human cytomegalovirus (HCMV)-derived peptides are critical components of the adaptive immune system's response to viral infection. These complexes, typically found on the surface of professional antigen-presenting cells, consist of an HLA class II heterodimer (such as HLA-DR, HLA-DQ, or HLA-DP) bound to a short peptide fragment derived from HCMV proteins like glycoprotein B (gB) or phosphoprotein 65 (pp65) (Hegde et al., 2003, Journal of Virology). The primary biological function of this complex is to be recognized by the T-cell receptor (TCR) of CD4+ T cells, which subsequently orchestrate a broad immune response through cytokine secretion and help for B cells and CD8+ T cells (Sissons et al., 2002, Journal of Infection). In the context of disease, HCMV is a major cause of morbidity in immunocompromised individuals and neonates, and the virus has evolved sophisticated mechanisms to downregulate HLA class II expression to evade detection (Neefjes et al., 2011, Nature Reviews Immunology). Therapeutic targeting of these complexes involves the development of vaccines designed to elicit robust CD4+ T-cell responses or the use of adoptive T-cell therapies to restore viral control in transplant patients (Plotkin, 2015, Vaccine).

Other names

MHC class II-HCMV peptide complexHLA-DR presenting HCMV peptidesHLA-DQ presenting HCMV peptidesHLA-DP presenting HCMV peptidesHCMV-specific HLA-II complexHLA-II-HCMV antigen complex

Stimulation of antigen-specific CD4+ T-cell receptors to trigger an adaptive immune response against HCMV-infected cells through cytokine release and B-cell help.